Bruker AXS Microanalysis To Launch QUANTAX(TM) QUAD, a Novel Ultra-Fast and Sensitive SDD Detector-based EDS System, at Pittcon 2006.

MADISON, Wis. -- Novel XFlash QUAD Detector for Spectral Imaging on Electron Microscopes

Bruker AXS Microanalysis, a division of Bruker AXS Inc., announces the international launch of QUANTAX(TM) QUAD, an innovative EDS system for X-ray microanalysis on electron microscopes, for Pittcon 2006.

QUANTAX(TM) QUAD features the unique XFlash(R) QUAD detector - the first four-channel 40 mm(2) Silicon Drift Detector (SDD) for Energy-Dispersive Spectroscopy (EDS) systems mounted on electron microscopes. Powered by ESPRIT(TM) software, the novel QUANTAX QUAD delivers significantly faster EDS results across a broad range of applications. It is especially suitable for field emission scanning electron microscopes, environmental and low vacuum scanning electron microscopes. The new high-end XFlash QUAD detector complements the existing Bruker AXS QUANTAX EDS product line.

Four independently operating 10 mm(2) Silicon Drift Detectors (SDDs) with integrated anodes and FETs form the heart of the XFlash QUAD detector. This arrangement provides the high energy resolution of a single 10 mm2 crystal at four times the count rate, accepting maximum input count rates in excess of 2,000,000 cps. Cooled by Peltier elements, the XFlash QUAD detector requires no liquid nitrogen and is vibration and maintenance-free. Standard energy resolution is better than 133eV (MnKa) at 10,000 cps, and energy resolution of less than 127 (MnKa, 10,000 cps) is available upon request.

Thomas Schuelein, Vice President for Microanalysis at Bruker AXS, stated: "This cutting-edge new product fits right into our broader EDS strategy, as it complements our already existing range of industry-leading Silicon Drift Detectors. While our proven 10 and 30 mm(2) single-channel XFlash SDDs are expected to remain the standard for the vast majority of EDS applications, the unique new XFlash QUAD SDD is ideal for optimizing count rate at low beam current conditions and helps make new analysis techniques, like spectral imaging, even more efficient and powerful. All of our QUANTAX EDS customers can upgrade to the XFlash QUAD in the future, should their applications require this performance."

Roger Durst, Ph.D., Executive Vice President of Bruker AXS, commented: "We are excited about introducing innovative products like this within our new Bruker AXS Microanalysis division. The strong technology synergies resulting from our recent X-ray microanalysis acquisitions have enabled us to introduce this novel and clearly performance-leading high-end QUAD SDD detector very rapidly."

For more information about the new QUANTAX QUAD and the complete line of X-ray microanalysis systems and detectors offered by Bruker AXS Microanalysis, please visit www.bruker-axs-ma.com and the Bruker AXS Pittcon booth, 3155, in Orlando, FL, on March 13-16, 2006.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.